

**In the Claims:**

Please cancel claim 25.

Please replace claims 1, 3-5, 9, 11, 17-19 and 21- 23 with the following versions. |

Sub  
B'  
A2

~~1. (Amended) A pharmaceutical composition for topical administration comprising:  
at least 5% by weight, based on the total weight of the composition, of a piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof;  
an acid in an amount to substantially completely solubilise the piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof;  
a solvent selected from water and/or a lower alcohol; and  
a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols; wherein when the co-solvent includes propylene glycol, it is present in an amount of less than approximately 10% by weight.~~

Sub  
B'  
A3

~~3. (Amended) A pharmaceutical composition according to Claim 1, wherein the piperidinopyrimidine derivative or pharmaceutically acceptable salt thereof is present in an amount of from approximately 5 to 25% by weight, based on the total weight of the pharmaceutical composition.~~

~~4. (Amended) A pharmaceutical composition according to Claim 3, wherein the piperidinopyrimidine derivative or pharmaceutically acceptable salt thereof is present in an amount of approximately 7.5 to 12% by weight, based on the total weight of the pharmaceutical composition.~~

~~5. (Amended) A pharmaceutical composition according to Claim 1, wherein the piperidinopyrimidine derivative or pharmaceutically acceptable salt thereof is minoxidil or a salt thereof.~~

A4 Sub B1 > 9. (Amended) A pharmaceutical composition according to Claim 1, wherein the composition includes water and ethanol in a range of approximately 1:1 to 1:3 by volume.

A5 Sub B1 > 11. (Amended) A pharmaceutical composition according to Claim 1, wherein the composition includes water and benzyl alcohol wherein the benzyl alcohol is in an amount of approximately 40 to 100% by weight based on the total weight of the co-solvent system.

Sub B1 > A6 17. (Amended) A pharmaceutical composition according to Claim 1, wherein the composition includes water and ethanol in a range of approximately 9:1 to 1:9 by volume.

18. (Amended) A pharmaceutical composition according to Claim 5, wherein the piperidinopyrimidine derivative or pharmaceutically acceptable salt thereof is a minoxidil salt.

19. (Amended) A pharmaceutical composition according to Claim 18, wherein the minoxidil salt is minoxidil acetate or minoxidil lactate.

Sub B1 > A7 21. (Amended) A method for the treatment of hair loss and related indications in humans, comprising the steps of:  
providing a pharmaceutical composition for topical administration having at least 5% by weight, based on the total weight of the composition, of a piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof; an acid in an amount to substantially completely solubilise the piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof; a solvent selected from water and/or a lower alcohol; and a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols; wherein when the co-solvent includes propylene glycol, it is present in an amount of less than approximately 10% by weight; and applying topically to the human scalp a therapeutically or prophylactically effective amount of the pharmaceutical composition.